Elevara Medicines Names Mai-Britt Zocca CEO as Emma Tinsley Moves to Board

Elevara Medicines has appointed biotech veteran Dr Mai-Britt Zocca as chief executive, with founder and outgoing CEO Emma Tinsley moving to the board as a non-executive director. The London clinical-stage biotech announced the leadership change on 14 July and said Zocca's appointment was effective from 1 July 2026.

The leadership transition is significant because Elevara is moving from founder-led formation into a more advanced clinical-development phase. The company is developing therapies for rheumatoid arthritis and other chronic inflammatory diseases. Its lead candidate, ELV001, is being studied in the Phase 2b START-SYNERGY trial, which began in March 2026 and is expected to involve 180 patients with inadequate responses to methotrexate and TNF inhibitors. The primary endpoint is change in DAS28-CRP at week 12, a validated measure of rheumatoid arthritis disease activity.

Zocca brings a founder-operator record of her own. Before joining Elevara, she founded and served as chief executive of IO Biotech, a Nasdaq-listed clinical-stage biopharmaceutical company developing cancer vaccines. Elevara said that under her leadership IO Biotech advanced its pipeline from Phase 1 through multiple Phase 2 trials and into a pivotal global Phase 3 clinical trial. She also previously founded and led a biotechnology venture focused on repurposing small molecules for cancer and neurodegenerative diseases.

That background explains why Elevara is framing the appointment around growth and execution. Early biotech companies need scientific credibility, but they also need leaders who can manage clinical trials, investor expectations, regulatory pathways, partnerships and capital discipline. Zocca's experience across company formation, public markets and late-stage trial progression matches the kind of operational load Elevara now faces.

Tinsley's move to the board also matters. Founder transitions can be delicate because the company has to preserve the knowledge and conviction that built the platform while adding the operating structure required for the next stage. Elevara said Tinsley will remain involved as a non-executive director, giving the company continuity while handing day-to-day leadership to Zocca.

The financing context is material. Elevara raised a $70 million Series A in October 2025, led by Forbion and Sofinnova Partners, with founding investor Monograph Capital and Weatherden also involved. The company said proceeds are funding ELV001 clinical development and supporting exploratory programs in other chronic inflammatory conditions and women's health. That investor base raises expectations because a large Series A gives the company resources, but it also creates pressure to show clinical progress.

For SheMeansNews, the story sits at the intersection of women's health, science leadership and founder succession. Rheumatoid arthritis affects many women, and the company is also exploring women's health programs. At the same time, the leadership team itself shows two women at different points of the company-building cycle: Tinsley as founder moving into board stewardship, and Zocca as a seasoned biotech CEO taking the company through a clinical inflection point.

Zocca said she was attracted by the differentiated science behind ELV001 and by the work already done by Tinsley and the team. She described the candidate as having the potential to become a cornerstone of the next treatment paradigm in rheumatoid arthritis. That is a forward-looking statement, not a clinical outcome. The trial still has to produce data. But the appointment signals that Elevara is preparing for the demanding work between a promising mechanism and a meaningful treatment option for patients.